Peer-reviewed veterinary case report
Matrine shows promise against canine mammary tumors in lab tests
By Noor, Fida et al.·Published in Veterinary immunology and immunopathology·2025·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Matrine as a potent inhibitor of canine mammary tumors: Insights from network pharmacology, molecular docking, molecular dynamics and in vitro analysis.
- Species:
- dog
Plain-English summary
A study found that matrine, a compound with anti-tumor properties, may help treat mammary tumors in female dogs. Researchers tested its effects on canine mammary tumor cells and discovered that matrine significantly reduced cell growth and migration over time, especially at higher concentrations. The treatment showed promising results in laboratory settings, with over 50% inhibition of tumor cell growth after 48 hours at a specific dose. While these findings are encouraging, further research is needed to see how effective matrine is in actual dogs with mammary tumors.
People also search for: dog mammary tumor treatment · matrine for canine cancer · female dog tumor symptoms
Abstract
Canine mammary tumor (CMT) is the most prevailing neoplasms in female dogs. Matrine demonstrates anti-tumor effects in various organs, its mechanism in CMT treatment remains unclear. This study involved in network pharmacology, molecular docking, dynamics simulations, cell viability, inhibations and migration, to clarify matrine's therapeutic action against CMT. Potential gene/protein targets were identified through PubChem (Matrine), and GeneCards (CMT), with point of intersection targets analyzed via STRING PPI network and Cytoscape. Top 10 hub genes were selected for gene ontology/KEGG pathway analyses (p < 0.05). Molecular docking (JAK2, AR, HDAC2, HDAC6, and NR3C1) revealed strong matrine-JAK2 binding (-7.8 kcal/mol), and dynamics simulations were confirmed by molecular dynamics simulations. Pathway analysis implicated JAK-STAT and PI3K-Akt signaling in matrine's as anti-tumor effects. In vitro results showing that the maximum noncytotoxic concentrations of matrine of canine primary mammary epithelial cells (cPMECs), where the cell viability remained above 90 % at concentrations 280 µM and ≤ 560 µM, respectively, indicating this as the maximum safe concentration for cPMECs, and had a proliferation inhibitory effect time-dependently (12, 24, 48 hrs) on CHMm and CHMp cells within a safe concentration range, and suppression of CMT cells via CCK-8 assays. In 12 h, moderate inhibition was detected, which increased at 24 h, and was most prominent at 48 h. The migration ability of cells decreased at 24 h, respectively. Notably, the 560 µM concentration resulted in over 50 % inhibition in both cell lines after 48 h. Future research should investigate in vivo efficacy to progression matrine as a veterinary oncotherapeutic.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41151296/